Profile data is unavailable for this security.
About the company
Acasti Pharma Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. It is focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using its drug delivery technologies. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. Its other pipeline drug candidates: GTX-102 and GTX-101. GTX-102 is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia. GTX-101 is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
- Revenue in USD (TTM)0.00
- Net income in USD-11.45m
- Incorporated2002
- Employees32.00
- LocationAcasti Pharma Inc103 Carnegie Center, Suite 300PRINCETON 08540United StatesUSA
- Phone+1 (450) 686-4555
- Fax+1 (450) 686-2505
- Websitehttps://www.acasti.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.20m | 91.00 | -- | 0.6521 | -- | 0.4551 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Nexgel Inc | 5.01m | -3.39m | 18.54m | 19.00 | -- | 4.16 | -- | 3.70 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 19.72m | 1.00 | -- | 0.7127 | -- | 19.80 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.13m | -20.74m | 20.37m | 8.00 | -- | -- | -- | 17.99 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 23.49m | 74.00 | -- | -- | -- | 9.78 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -24.70m | 24.33m | 59.00 | -- | 10.37 | -- | -- | -9.65 | -9.65 | 0.00 | 0.3337 | 0.00 | -- | -- | 0.00 | -107.89 | -76.92 | -164.39 | -89.61 | -- | -- | -- | -- | -- | -24.21 | 0.8425 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Bio Essence Corp | 593.21k | -1.02m | 25.09m | 12.00 | -- | -- | -- | 42.29 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| KALA BIO Inc | 0.00 | -38.72m | 26.68m | 43.00 | -- | 1.94 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Acasti Pharma Inc | 0.00 | -11.45m | 27.17m | 32.00 | -- | 0.4578 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Dare Bioscience Inc | 2.84m | -7.20m | 27.86m | 23.00 | -- | 10.43 | -- | 9.81 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Equillium Inc | 42.62m | -8.32m | 30.11m | 45.00 | -- | 1.34 | -- | 0.7064 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 30.95m | -- | -- | 2.19 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 34.11m | 186.00 | -- | 1.89 | -- | 0.4128 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Ocuphire Pharma Inc | 16.45m | -14.11m | 36.42m | 14.00 | -- | 0.8886 | -- | 2.21 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Acasti Pharma Inc's reporting currency: US Dollar USD
21.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adar1 Capital Management LLCas of 30 Jun 2024 | 959.57k | 9.46% |
| AIGH Capital Management LLCas of 30 Jun 2024 | 641.08k | 6.32% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 494.70k | 4.88% |
| G1 Execution Services LLCas of 30 Jun 2024 | 37.79k | 0.37% |
| UBS Securities LLCas of 30 Jun 2024 | 7.74k | 0.08% |
| RBC Capital Markets LLC (Investment Management)as of 30 Jun 2024 | 6.00k | 0.06% |
| National Bank Financial, Inc.as of 30 Jun 2024 | 2.90k | 0.03% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.85k | 0.02% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Jun 2024 | 584.00 | 0.01% |
| Activest Wealth Management LLCas of 30 Jun 2024 | 104.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
